ProCE Banner Activity

An Expert’s Guide to WCLC 2022: A Preview of the Top Abstracts

Clinical Thought
Read about key studies highlighted by experts being presented at the upcoming IASLC 2022 WCLC annual meeting. The CCO WCLC Conference Coverage program will have the information you need to understand and integrate the latest oncology data into your clinical practice.

Released: August 05, 2022

Expiration: August 04, 2023

Share

Faculty

Wade T. Iams

Wade T. Iams, MD, MSCI

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Heather Wakelee

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Wade T. Iams, MD, MSCI

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Wade T. Iams, MD, MSCI: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, EMD Serono, Janssen, Jazz, Mirati, Takeda.

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Heather Wakelee, MD: consultant/advisor/speaker: Mirati; researcher: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, Bristol Myers Squibb, Clovis Oncology, Genentech/Roche, Helsinn, Merck, Novartis, SeaGen, Xcovery.